Two tau-focused developments moved the Alzheimer’s field forward on both mechanism and measurement. In preclinical work led by Stanford Medicine, chemically modified tau was reported to enter mitochondria and disrupt the energy-producing electron transport machinery, triggering reverse electron transport and downstream neurodegenerative effects. Separately, a study examining plasma pTau217 reported diagnostic performance across genetically admixed South American populations, extending biomarker validation beyond the ancestry groups most represented in earlier evidence. Together, the findings support a dual track: mechanistic hypotheses that may enable new therapeutic blocking strategies and more inclusive biomarker validation that can improve real-world diagnostic and trial enrichment accuracy. For drug developers, the mitochondrial tau mechanism—if translated—offers additional intervention points beyond aggregation-centric targets, while the biomarker expansion informs how patient selection and endpoints might be standardized across diverse cohorts.